Autopsy report · NCT03258723

Diabetes Prevention With Lifestyle Intervention and Metformin Escalation

“COVID-19 led to changes in study design and an early end to data collection.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months before it started.
• Ran for about 3 years 4 months before it stopped.
• 114 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Yale University

Sponsor type

University, hospital or other

Conditions

Diabetes

Interventions

Lifestyle Intervention; Metformin

Participants

114

Sites

4

Countries

Barbados, Puerto Rico, Trinidad and Tobago, Virgin Islands

Trials that died the same way

• Better Together: Reablement and Caregivers
  “Due to COVID-related issues had to change study design.” (76% match in meaning)
• Vitamin D Status and Bone Health of Older Adults in Care Facilities
  “COVID-19, study status being reviewed on an ongoing basis.” (71% match in meaning)
• Effects of Short-term Choir Participation on Auditory Perception in Hearing-aided Older Adults.
  “COVID-19 forced the shut down of the study” (71% match in meaning)
• The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
  “Study ended early due to COVID-19” (70% match in meaning)
• Improving 24-hour Blood Pressure in Obstructive Sleep Apnea
  “Covid-19 Pandemic prevented this study from beginning” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.